An FDA First Adds To Rock Creek’s Regulatory Adventures
This article was originally published in The Tan Sheet
Executive Summary
FDA “for the first time” notified tobacco retailers about products found to be not substantially equivalent for sale, with each of the 16 warnings identifying Rock Creek’s Ariva and Stonewall Jackson nicotine lozenges. The firm continues turning its operations to drug development after FDA rejected a NDI notification.
You may also be interested in...
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.